Here's Why Bitcoin Could Rise to $165,000 Starting Exactly On April 22, 2024.
The same catalyst the kicked off the three major crypto bull markets... is about to hit again on April 22, 2024
Here's what you need to do now to profit.
Robert  Chess net worth and biography

Robert Chess Biography and Net Worth

Director of Twist Bioscience
Rob Chess is a serial entrepreneur in the life sciences field. He currently is Chairman of Nektar Therapeutics, (NASDAQ:NKTR), a health care biotechnology company, and serves as lead director of Twist Biosciences (NASDAQ:TWST), which is a leading company in the synthetic biology field. Rob joined Nektar as its first non-founder employee in 1991 and led the company as CEO through 1999 and as Chairman since then. Rob co-founded and was President of Penederm, a dermatology company that went public and was acquired by Mylan Laboratories, and was the start-up CEO and later Chairman of OPX Biotechnologies, a renewable chemicals company which was sold to Cargill. He also is the co-founder and former Chairman of Biota Technologies, which is pioneering the use of DNA sequencing for energy and other industrial applications.  He started his career in the technology field and held management positions at Intel and Metaphor Computer Systems (later acquired by IBM). Rob served on the White House Staff in the first Bush Administration as a White House Fellow and Associate Director of the White House Office of Economic and Domestic Policy.

In addition to his entrepreneurial endeavors and activities at the Stanford GSB, Rob is a trustee of Caltech and Chairman of the Caltech Board Technology Transfer Committee. He also was the initial Chairman and is now a Board member of Bio Ventures for Global Health, and was a long-time Board member of the Biotechnology Industry Organization where he was chairman of the Emerging Companies Section and co-chairman of the Intellectual Property Committee. Rob received a BS in engineering with honors from Caltech and an MBA from Harvard.

Rob is an out-of-practice but avid golfer, a reformed political junkie, and father of 24-year-old triplets.

What is Robert Chess' net worth?

The estimated net worth of Robert Chess is at least $2.44 million as of February 8th, 2024. Mr. Chess owns 64,169 shares of Twist Bioscience stock worth more than $2,439,705 as of February 23rd. This net worth estimate does not reflect any other investments that Mr. Chess may own. Learn More about Robert Chess' net worth.

How do I contact Robert Chess?

The corporate mailing address for Mr. Chess and other Twist Bioscience executives is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. Twist Bioscience can also be reached via phone at (800) 719-0671 and via email at [email protected]. Learn More on Robert Chess' contact information.

Has Robert Chess been buying or selling shares of Twist Bioscience?

In the last ninety days, Robert Chess has sold $143,767.80 in shares of Twist Bioscience stock. Most recently, Robert Chess sold 4,110 shares of the business's stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $34.98, for a transaction totalling $143,767.80. Following the completion of the sale, the director now directly owns 64,169 shares of the company's stock, valued at $2,244,631.62. Learn More on Robert Chess' trading history.

Who are Twist Bioscience's active insiders?

Twist Bioscience's insider roster includes William Banyai (Insider), Robert Chess (Director), Keith Crandell (Director), Mark Daniels (Insider), Patrick Finn (Insider), Paula Green (SVP), Jan Johannessen (Director), Emily Leproust (CEO), James Thorburn (CFO), and Patrick Weiss (COO). Learn More on Twist Bioscience's active insiders.

Are insiders buying or selling shares of Twist Bioscience?

In the last year, Twist Bioscience insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $132,000.00. In the last year, insiders at the sold shares 1 times. They sold a total of 4,110 shares worth more than $143,767.80. The most recent insider tranaction occured on February, 8th when Director Robert Chess sold 4,110 shares worth more than $143,767.80. Insiders at Twist Bioscience own 3.9% of the company. Learn More about insider trades at Twist Bioscience.

Information on this page was last updated on 2/8/2024.

Robert Chess Insider Trading History at Twist Bioscience

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/8/2024Sell4,110$34.98$143,767.8064,169View SEC Filing Icon  
2/4/2022Sell253$58.88$14,896.64View SEC Filing Icon  
11/1/2021Sell4,000$120.15$480,600.00View SEC Filing Icon  
10/21/2021Sell3,700$120.15$444,555.00View SEC Filing Icon  
10/19/2021Sell300$120.00$36,000.00View SEC Filing Icon  
9/10/2021Sell4,000$120.23$480,920.0059,014View SEC Filing Icon  
7/12/2021Sell4,000$125.91$503,640.0066,404View SEC Filing Icon  
6/23/2021Sell4,000$120.10$480,400.0067,014View SEC Filing Icon  
2/5/2021Sell706$159.54$112,635.2471,014View SEC Filing Icon  
See Full Table

Robert Chess Buying and Selling Activity at Twist Bioscience

This chart shows Robert Chess's buying and selling at Twist Bioscience by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Twist Bioscience Company Overview

Twist Bioscience logo
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $38.20
Low: $37.68
High: $38.73

50 Day Range

MA: $36.21
Low: $32.28
High: $41.50

2 Week Range

Now: $38.20
Low: $11.46
High: $43.21


597,372 shs

Average Volume

1,084,659 shs

Market Capitalization

$2.21 billion

P/E Ratio


Dividend Yield



Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment.